TITLE

Health issues for pregnant dental staff and dental patients for the 2010 winter "flu" season

AUTHOR(S)
Walsh, Laurence J.
PUB. DATE
January 2010
SOURCE
Auxiliary;Jan/Feb2010, p22
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article focuses on health concerns for pregnant dental patients and staff during the 2010 winter season when influenza can produce medical complications. The risk group for medical complications from influenza and H1N1 (swine flu) include pregrant women, breastfeeding mothers and children. The article offers information on the H1N1 2009 vaccine Panvax, antiviral drugs including Oseltamivir or Tamiflu and Zanamivir or Relenza and a list of pandemic influenza symptoms including fever, coughing and sore throat.
ACCESSION #
52287203

 

Related Articles

  • Tamiflu Value Sparks Questions. Siew, Adeline // Pharmaceutical Technology Europe;May2014, Vol. 26 Issue 5, p6 

    The author reflects on the review of the article "Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments" by Cochrane Collaboration, an independent organization that organizes medical research information. She mentions...

  • Roche to give access to all Tamiflu data.  // PharmacoEconomics & Outcomes News;4/13/2013, Issue 676, p4 

    The article reports on the announcement by pharmaceutical company Roche that it will provide Cochrane researchers access to all 74 of its trials on its influenza drug oseltamivir.

  • Pharma Acts on Swine Flu.  // Pharmaceutical Executive;May2009, Vol. 29 Issue 5, p13 

    The article reports on the move of the pharmaceutical industry to lessen the spread of swine flu in the U.S. As stated, swine flu can be treated with two existing antiviral treatments such as Relenza from GlaxoSmithKline and Tamiflu by Roche/Gilead. With regards to the attack of the virus, the...

  • The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. Doshi, Peter; Jefferson, Tom; Mar, Chris Del // PLoS Medicine;Apr2012, Vol. 9 Issue 4, p1 

    The article provides information on the failure of influenza antiviral Tamiflu (oseltamnivir) to reduce complications. The U.S. Food and Drug Administration (FDA) mentioned that Tamiflu had been revealed to lessen complications and needed an explicit statement label of the drug to that effect....

  • Research questions £400m flu drug stockpile.  // GP: General Practitioner;4/14/2014, p44 

    The article discusses a study by the nonprofit organization Cochrane Collaboration, which indicates that the influenza drug oseltamivir (Tamiflu) does not reduce serious complications or hospital admissions from flu. Topics addressed include money wasted by the British government by stockpiling...

  • Roche, Under Fire, Offers Compromise in Flu-Drug Dispute.  // MondayMorning;11/26/2012, Vol. 20 Issue 45, p1 

    The article offers information about the dispute regarding the use of flu drug Tamiflu from Switzerland-based Roche Holding AG. It informs that the drug has been approved by regulators but the researchers have asked the company to provide clinical trials data for further review of the drug. It...

  • Treatment with NanoViricides FluCide(tm) Drug Candidates Resulted in a 1000-fold Reduction of Viral Load in the Lungs of Animals Infected with Lethal Dose of Influenza Virus.  // Biomedical Market Newsletter;5/5/2011, p459 

    The article presents a study on the effect of Nanoviricides Inc.'s flucide drug on animals infected with influenza virus which reports a 1000-fold reduction in the levels of virus in animal's lungs. It is stated the drug increases animal survival and lung protection from tissue damage. It offers...

  • Neuraminidase inhibitors: the story behind the Cochrane review. Doshi, Peter // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/12/2009, Vol. 339 Issue 7734, p1348 

    The article explores the inconsistent and fragmented evidence for the use of the global public health drug oseltamivir from Roche for pandemic influenza as discovered by the team updating the Cochrane review of neuraminidase inhibitors. A review of neuraminidase inhibitors was commissioned by...

  • What can we learn from observational studies of oseltamivir to treat influenza in healthy adults? Freemantle, Nick; Calvert, Mel // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/12/2009, Vol. 339 Issue 7734, p1352 

    The article investigates the limited value of studies of the use of the antiviral drug oseltamivir to treat influenza in healthy adults identified by Roche. It discusses the problems associated with randomised controlled trials as a basis for examining the effects of the drug. It examines the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics